| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3235181 | Apollo Medicine | 2008 | 5 Pages |
The appropriate management of hematological disorders must rely on a precise and long-term monitoring of the patient's response to chemotherapy and radiotherapy. The presence of residual malignant cells among normal cells is termed minimal residual disease (MRD). Nowadays a great progress has been made in the treatment of malignant diseases and in the development of reliable molecular techniques, which are characterized by high sensitivity and ability to distinguish between normal and malignant cells at diagnosis and during follow-up. Especially, MRD data based on quantitative analysis (RQ-PCR) appear to be crucial for appropriate evaluation of treatment response in CML. Implementation of standardized approaches for MRD assessment into routine molecular diagnostics available in Immunology & Molecular Biology Lab at Indraprastha Apollo Hospital, New Delhi should be regarded nowadays a crucial point in further MRD study.In the present paper, authors have made an attempt to present the benefits of IVD Certified Platform for monitoring MRD in CML patient at the Molecular and Immunology lab, Indraprastha Apollo Hospitals, New Delhi during the year 2007-2008.
